The US Food and Drug Administration’s September drug safety communication on cardiovascular and cancer risks posed by the Janus kinase inhibitor class of drugs means thatAbbVie Inc.’s oral rheumatoid arthritis therapy Rinvoq (upadacitinib) soon will get a revised label, but the pharma’s top execs expressed confidence about growth projections for the JAK inhibitor during a 29 October sales and earnings call, even if the safety update is restrictive.
In its 1 September announcement that Pfizer Inc.’s Xeljanz (tofacitinib) will add a black box warning after a post-marketing...